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Multiple sclerosis (MS) is considered to be an autoimmune demyelinating disorder of the central 
nervous system (CNS), which leads to disruptions in sensory, motor, and/or cognitive systems. 
In addition to these disruptions, patients with MS have an elevated risk for various comorbidities. 
In order to provide comprehensive patient care, a proper understanding of these comorbidities is 
required.
The risks for various cardiovascular diseases (CVDs) have been examined in MS patients [reviewed 
in Ref. (1)], and ischemic stroke is one of the CVDs. Although an increased risk for ischemic stroke 
has been described for patients with MS, issues have been raised to question whether the observed 
elevated risk is valid. Since individuals who have an elevated risk for ischemic stroke are often given 
preventive treatment, clarifying whether MS patients have an actual elevated risk for ischemic stroke 
is an important first step in determining whether these patients, or a subgroup of patients, should be 
placed on a preventive treatment regimen.
A study by Roshanisefat et  al. (2) determined that the relative risk for ischemic stroke was 
increased in patients with MS during the initial year of diagnosis, with statistical significance being 
lost if data from the initial period was removed from the analysis. Other studies (3, 4) also observed 
an elevated risk for ischemic stroke (or unspecified stroke) during the first year of diagnosis, although 
unlike the findings by Roshanisefat et al. (2), the increased risk persisted over the long term, albeit 
less than for the initial year. Additional studies, likewise, found a heightened risk for stroke in MS 
patients [reviewed in Ref. (1)], and multiple reports have described cerebral venous thrombosis in 
MS patients (5–8).
Roshanisefat et al. (2) provided the reasonable explanation that surveillance bias (e.g., an increased 
frequency of neuroimaging during the initial period) was probably responsible for the apparent 
elevated risk during the first year. In addition, Roshanisefat et al. (2) discussed that misdiagnosis of 
lesions could have contributed to the observed elevated risk, and the possibility of misclassification 
was raised by Allen et  al. (9). These reasons were echoed by us in a review (10), and published 
reports describe examples of diagnostic challenges between MS and stroke (11–13). Together, these 
explanations questioned the accuracy of the findings of an increased risk for stroke in patients with 
MS. However, weighing of additional factors indicates that the increased risk might be valid.
The loss of a statistically significant increased risk of stroke in MS patients after excluding the 
initial year (2) could be accounted for by two mechanisms. First, it is possible that once a patient 
is diagnosed with MS, then stroke is underdiagnosed due to attributing findings consistent with 
stroke to the MS disease itself. The possibility that stroke was misdiagnosed as a MS flare during 
early years, e.g., 1977–1996, was put forward by Christiansen et al. (3). Second, the implementation 
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of a disease-modifying therapy (DMT) would lessen inflamma-
tory events, and thereby possibly lessen the occurrence of stroke. 
This might also explain why some other comorbidities also 
display a decreased relative risk after the initial year of diagnosis, 
e.g., pulmonary embolism across a wide range of autoimmune 
disorders (14).
It turns out that multiple autoimmune diseases have an 
increased risk for ischemic stroke. For example, besides MS or 
vasculitis, bullous pemphigoid and rheumatoid arthritis are asso-
ciated with an increased risk for stroke (15, 16). The occurrence 
of antiphospholipid antibodies is also associated with stroke. 
Patients with antiphospholipid syndrome have autoantibodies 
that target phospholipids leading to an increased risk of vascular 
thrombosis with stroke being among the more common throm-
botic events (17). The presence of antiphospholipid antibodies to 
β2glycoprotein I is associated with an increased risk of stroke in 
patients with systemic lupus erythematosus with neuropsychiatric 
manifestations (18). Furthermore, antiphospholipid antibodies 
may be associated with stroke in patients with Sjögren’s syndrome 
(19). Antiphospholipid antibodies are more common in patients 
with MS than in healthy control subjects, and they appear to be 
more prevalent during relapse (20, 21). Thus, it is possible that 
antiphospholipid antibodies contribute to the generation of 
stroke in MS patients, which could account for, at least in part, 
the elevated risk of ischemic stroke in this patient population. 
Additionally, extensive cerebrovascular changes (e.g., platelet 
activation and hypoperfusion) occur in MS, and these changes 
could promote clot formation in the CNS (10, 22). Other factors 
that could contribute to the elevated risk of stroke in patients with 
MS are the increased prevalence of smoking and reduced physical 
activity in this patient population (1).
After evaluating the body of data listed above, in my view, 
surveillance bias and/or misdiagnosis do not fully account for 
the observed elevated risk for ischemic stroke in patients with 
MS. Instead, pathogenic mechanisms, some of which appear to be 
shared across multiple autoimmune diseases, are likely responsi-
ble, at least in part, for the greater risk of stroke in patients with 
MS. If correct, then this raises the issue of preventive treatment. 
There have been recent suggestions for pursing preventive 
measures directed against ischemic stroke in MS patients (4, 23). 
However, before considering a broad advisement for a preven-
tive treatment regimen for patients with MS, in my view, two 
main questions should be addressed. First, do all MS patients 
have an elevated risk for ischemic stroke or is the risk more, or 
predominantly, pronounced within a subgroup(s) of patients? 
Some studies observed an increased risk for young patients (3, 4) 
while another study observed a suggestion for greater trend in 
older patients (23). It would not be surprising if different disease 
courses of MS (clinically isolated syndrome, relapsing remitting 
MS, primary progressive MS, and secondary progressive MS) or 
different states of disease activity have different associated risks 
for ischemic stroke. Patients who have restricted mobility, who 
smoke, or who have antiphospholipid antibodies could represent 
a subgroup having a particularly high risk (10). Also, it is possible 
that a DMT is contributing to (23), or reducing, an elevated risk.
Obtaining clear and complete answers about the risks in 
subgroups of patients likely would be a difficult and prolonged 
task. However, one possibility would be to screen MS patients 
for known risk factors for ischemic stroke as these may pro-
duce a compounded risk (e.g., the risk due to MS itself plus 
the risk due to the additional risk factor for ischemic stroke). 
Furthermore, it is possible that these known factors actually 
account for the majority of the elevated risk in MS patients. 
Thus, patients with known risks for ischemic stroke may be 
more favorable candidates for preventive treatment (possible 
greater benefit-to-risk ratio for treatment); however, this brings 
us to the second question: does the pathogenesis of MS present 
a particular susceptibility for an adverse event in response to an 
intervention? For instance, low dose aspirin is often used as a 
preventive treatment for individuals with an increased risk for 
ischemic stroke, but given that disruption to the blood–brain 
barrier (BBB) is a common pathological feature in MS, and aspi-
rin increases the risk for hemorrhagic stroke and other bleeding 
events, it raises the question of whether aspirin could worsen 
BBB leakage (10). Given the importance of this potential issue, 
it is an area of investigation that I am interested in exploring in 
future research endeavors. I also encourage others to address the 
issues raised above. Once obtained, this information should be 
considered in the broader context of other comorbidities, so that 
a comprehensive picture can emerge about preventive treatment 
for patients with MS.
In summary, although the comorbidity of ischemic stroke for 
patients with MS is likely valid, I believe that there are outstand-
ing issues that should be considered before applying preventive 
treatment strategies for MS patients in a broad-based manner. 
These issues include making sure that a preventive treatment 
does not have adverse effects that are particular to this patient 
population and determining which subgroups of patients most 
likely will benefit from preventive treatment.
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